Low-grade astrocytomas are differentiated from the much more aggressive anaplastic astrocytomas and glioblastomas because they behave quite differently and are associated with a much better prognosis. Nevertheless, some low-grade astrocytomas progress rapidly and carry a poor prognosis. Several studies have tested the association of clinical and histological features of astrocytic tumours with clinical behaviour (Daumas-Duport et Schiffer et al., 1988; Burger, 1990) .
In low-grade astrocytomas the classical histological features alone have only limited value in predicting outcome (Soffietti et al., 1989) : therefore additional biological parameters which could improve prognostication have been intensely investigated. Among these parameters are the proliferative activity (Burger et al., 1986; Giangaspero et al., 1987; Hoshino et al., 1988; Allegranza et al., 1991; Jaros et al., 1992) , DNA content (Nishizaki et al., 1989) and alterations of oncogenes and tumour-suppressor genes (BaugnetMahieu et al., 1990; Venter & Thomas, 1991; Orian et al., 1992; Jaros et al., 1992; Haapasalo et al., 1993) .
The investigated tumour-suppressor genes include the p53 gene and its product, which have key functions in regulating cell proliferation (Mercer et al., 1990) , differentiation (Kastan et al., 1991a) , DNA repair (Kastan et al., 1991b; Lane, 1992) cell senescence and apoptosis (Shay et al., 1991; YonishRouach et al., 1991; Lane, 1992) . The p53 product is a nuclear phosphoprotein with short half-life and low nuclear concentration. In most normal tissues, the p53 protein (p53) nuclear concentration is below the threshold of detection of the usual immunohistochemical methods. Somatic mutations of the p53 gene are frequent genetic lesions in human neoplasms and the mutated p53 protein is usually more metabolically stable than the wild-type protein and accumulates in the nucleus (Finlay et al., 1989) , where it can be demonstrated by immunohistochemistry (Iggo et al., 1990) .
Altered expression of p53 has been associated with aggressive clinical behaviour in breast (Thor et al., 1992) , prostate (Visakorpi et al., 1992) and colon tumours (Sun et al., 1992) .
In brain tumours, p53 gene mutation and p53 protein accumulation have been documented in few cases of lowgrade astrocytomas (Sidransky et al., 1990; Barbareschi et al., 1992a; Ellison et al., 1992; von Deimling et al., 1992 von Deimling et al., , 1993 , are more frequent in high-grade tumours (Chung et al., 1991; Barbareschi et al., 1992a; Ellison et al., 1992; Jaros et al., 1992) and are associated with tumour progression (Hayashi et al., 1991; Ellison et al., 1992; Sidransky et al., 1992; Karamitopouluo et al., 1993) . The possible role of p53 overaccumulation as a prognostic factor in brain tumours has been suggested by Jaros et al. (1992) . In their series of low-and high-grade astrocytomas, p53 overexpression was associated with reduced survival. However, their number of low-grade tumours was too small to attempt a separate survival analysis. In the present study we investigated a series of 52 low-grade astrocytomas (grade II according to the World Health Organization; Kleihues et al., 1993) hyperplasia, microcysts, and microcalcifications. Performance status was evaluated with the Karnofsky score system, which is based on the presence or absence of clinical signs of the disease (high score, from 100 to 80), the inability to do normal activity or the requirement for frequent medical care (medium score, from 70 to 50), and the need for special care or hospitalisation (low score, from 40 to 10) (Karnofsky & Burchenl, 1949) . Cellular density was scored as low [<400 cells per high-power field (HPF)] and moderate (400-800 cells per HPF). High-grade nuclear polymorphism was seen only in two pleomorphic xanthoastrocytomas; among the other-tumours nuclear pleomorphism was graded as slight (31 cases) and moderate (33 cases). Mitotic figures were either absent or extremely rare. Vessels were scored as normal if their density was similar to the density of vessels in the normal brain tissue, and as increased if their density was higher than in normal brain. Endothelial hyperplasia was never seen in primary low-grade astrocytomas.
Fourteen primary tumours were not suitable for immunohistochemical evaluation because of fixation artifacts. Of the remaining 52 primary tumours, 20 were classified as fibrillary astrocytomas, 32 as protoplasmic astrocytomas and two as pleomorphic xanthoastrocytomas. Their five recurrences showed features of high-grade astrocytic tumours (four glioblastoma multiforme and one anaplastic astrocytoma). Median survival of the 52 patients was 38.5 months.
p53 immunoreactivity was evaluated with the monoclonal antibody (MAb) D07 (Vojtesec et al., 1992) as previously described (Dei Tos et al., 1993) . The antibody recognises an epitope of the human wild-type p53 protein between amino acids 1 and 45. Briefly, 4-itm-thick sections were cut from paraffin blocks and rehydrated. Endogenous peroxidase was blocked and the sections were incubated with normal nonimmune horse serum for 20 min at room temperature. The sections were then incubated for 2 h at room temperature with the primary antibody at 1:200 dilution; biotinylated horse anti-mouse IgG at 1:200 dilution and avidin-biotinperoxidase complex (ABC) at 1:100 dilution were added in sequence (Vectastain ABC Kit, Vector). Negative controls were obtained omitting the primary antibody; positive controls were sections of lung and laryngeal neoplasms known to express p53 or to bear p53 gene mutations (Barbareschi et al., 1992b; Maestro et al., 1992) .
In all p53-immunoreactive cases the staining was quantified on an Olympus BH2 microscope at 400 x using a square graticule. One thousand nuclei were counted in each case, and the percentage of p53-positive nuclei was recorded as the p53 labelling index (pS3LI). When regional heterogeneity of labelling was detected in the tumour, counting areas were chosen to include those with higher density of p53-positive cells. Tumours were considered p53 positive if more than 1% of the cells showed nuclear staining.
Statistical analysis was performed using the SAS System (PROC LIFETEST and PROC PHREG) run on an HP Vectra 386-25 (IBM compatible). Survival was estimated by the method of Kaplan-Meier and differences between curves were tested for statistical significance with the log-rank test. Multivariate analysis of the main clinical and histological parameters (P-values in the univariate analysis < 0.10) was performed using the Cox proportional hazard method in a stepwise manner.
Results
Univariate analysis of histological parameters showed that only the presence of microcalcifications was statistically associated with prolonged survival (P = 0.03); the presence of microcysts showed a similar trend but did not reach statistical significance (P = 0.1). Multivariate statistical analysis of the clinical and histological parameters with the Cox proportional hazards model demonstrated that preoperative Karnofsky score and the extent of surgery were by far the most important variables in predicting length of survival (P = 0.0001 and P = 0.0007 respectively in univariate analysis, see Table I ; the results of multivariate analysis are reported in Table II) , whereas no histological parameter provided statistically significant prognostic information.
p53 immunolabelling was not observed in normal nervous tissue adjacent to the tumours, as previously reported by us (Barbareschi et al., 1992a) . p53 immunostaining was detected in nuclei in 32 out of 52 tumours (61.5%) (Figure 1 ). pS3LI ranged from 0.1% to 40%. Eight cases (15.4%) with only rare positive cells (less than 1% of the cells) were considered negative for p53 accumulation (see Table III ). Heterogeneous distribution of p53-immunoreactive cells was frequently seen, especially in tumours with high pS3LI. The intensity of nuclear labelling within the tumours also varied: lesser or more intensely immunoreactive nuclei were randomly intermingled.
The clinical data of the groups of p53-positive and p53-negative patients are shown in Tables IV and V. Age, completeness of surgical resection, Karnofsky status and site of the tumours were similarly distributed in the two groups of patients.
Median survival for p53-positive and p53-negative patients was 41 and 37 months respectively. The survival curves of p53-positive and -negative patients are shown in Figure 2 . The curves do not show statistically significant differences. Similar results were also obtained when we subdivided the cases in three groups, i.e. negative, low positive with pS3LI >1 and <10%, and highly positive with pS3LI > 10% (Figure 3) .
Although there are no statistically significant differences in survival between p53-positive and -negative tumours, the curves show a trend towards a more aggressive course in p53-positive patients 4 years after surgery, where the curves diverge. In fact, 5 years after diagnosis the survival estimate with the Kaplan-Meier method is only 21.2% for patients with p53-positive tumours, while at the same time the estimated survival for patients with p53-negative tumours is 45.9%. However the small number of patients alive after 5 years does not allow valid separate analysis.
In five patients recurrences were surgically removed: one case was an anaplastic astrocytoma and the others glioblastomas. The recurrences derived from four p53-positive tumours (mean pS3LI 5%, range 3-13%) and one neoplasm with only occasional p53-positive cells (pS3LI = 0.1%). All recurrent tumours were themselves p53 positive, with high pS3LI (mean pS3LI 55%, range 20-90%).
Discussion
This study demonstrates that histological parameters are of little value in predicting the outcome of patients suffering from low-grade astrocytomas, highlighting the need for additional biological parameters to improve outcome prediction in this group of patients.
In the present series of low-grade astrocytomas we show p53 immunoreactivity in 46% of patients with wide range of percentage of nuclear staining. No statistically significant differences in survival curves were observed between p53-positive and p53-negative patients. However p53-positive patients showed a trend towards worse prognosis.
p53 gene mutation and p53 protein accumulation have been documented in low-and high-grade astrocytomas, and it has been suggested that p53 mutation occurs in the initial stages of tumour formation (Ellison et al., 1992; Deimling et al., 1992 Louis et al., 1993) . This is in keeping with the demonstration that loss of heterozygosity for loci on the short arm of chromosome 17 (17p) (where the p53 gene is located) is shared by cells in each malignancy stage (ElAzouzi et al., 1989; James et al., 1989 James et al., , 1990 Bigner & Vogelstein, 1990; Venter & Thomas, 1991; Cavenee, 1992; von Diemling et al., 1993) . p53 gene and protein alterations could indeed be an early event in tumour progression, which may be associated with clinical aggressiveness. It might therefore be hypothesised that p53 protein accumulation (Karnofsky & Burchenl, 1949) . not find a statistically significant difference between the survival of p53-positive and p53-negative patients. However, 3-4 years after surgical intervention and diagnosis the survival curves showed a trend towards a shorter survival for p53-positive patients. The trend for a more aggressive course in p53-positive patients is even more evident considering that at 5 years follow-up the survival estimate with the KaplanMeier method is only 21.2% for patients with p53-positive tumours, while at the same time the estimated survival for patients with p53-negative tumours is 45.9%. It is unlikely that this trend is due to factors such as age, incomplete resection, Karnofsky status or site of the tumours, since there were no major differences in the above parameters in the two groups of patients. The fact that the trend is not apparent until 3-4 years follow-up could be interpreted as being a consequence of the time needed for the p53-positive subclone to outgrow the rest of the p53-negative neoplastic cell population. The long time needed for the p53-positive subclone to overgrow the other cells could be related to the low proliferative activity of low-grade astrocytomas (Giangaspero et al., 1987; Hoshino et al., 1988; Allegranza et al., 1991) .
The hypothesis of the clonal expansion of the p53-positive neoplastic cells is further supported by the fact that all five patients in our series in whom we could examine a recurrent tumour were at least focally p53-positive and the recurrent tumours were themselves intensely p53 positive, with a pS3LI more than ten times higher than the primitive neoplasms. These recurrent tumours could be the expression of the clonal expansion of the pre-existing p53-positive clones, in keeping with the hypothesis of Sidransky et al. (1992) .
The fact that the recurrent tumours that we could analyse were histologically malignant (one grade III astrocytoma and four glioblastomas) could be related to the fact that, once a tumour is composed mainly of a p53-positive genetically unstable cell population (Lane, 1992) , the likelihood of further genetic damage is greater and specific additional structural changes, for example on chromosome 10, could be more frequent, leading to the development of a highly aggressive tumour (Bigner & Vogelstein, 1990; von Diemling et al., 1993) . In this view the four recurrences with histological features of glioblastomas could be interpreted as type 1 glioblastomas according to von Diemling et al. (1993) .
The present study thus suggests the following conclusions: (1) p53 protein accumulation in the nuclei of low-grade astrocytomas is a frequent event (more than 40% of cases are positive). (2) p53 accumulation is not associated with statistically significant differences in survival, despite a trend for p53-positive tumours to be more aggressive. (3) The trend for a more aggressive course is apparent after a latency period of 3-4 years from diagnosis, which could be related to the time needed by the p53-positive clone to expand; this fact was further supported by widespread p53 positivity observed in recurrences.
